Omeza
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Omeza sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Omeza: 6 sponsored US clinical trials, 1 recruiting.
Omeza sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Venous Leg Ulcer, with 1 trials.
Upper-quartile sponsor footprint
Omeza sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers
NCT07161830
Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers
NCT05417425
Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies
NCT05921292
Omeza Combination Therapy With Standard of Care to Standard of Care Alone for Chronic Venous Leg Ulcers
NCT05291169
Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT
NCT04510675
Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method
NCT04510376
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
What is open in the Omeza pipeline
1 recruiting of 6 indexed (17% open); 5 completed (83%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Venous Leg Ulcer (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Omeza: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Omeza sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Omeza page
6 registered trials is a research-attention snapshot, not an endorsement of Omeza or any single study.
- 1 of Omeza's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Venous Leg Ulcer is the condition Omeza studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Venous Leg Ulcer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Omeza pipeline card: 6 registered trials from official public datasets.Report a data error.